TPWA
ENTA icon

Twin Peaks Wealth Advisors’s Enanta Pharmaceuticals ENTA Stock Holding History

Twin Peaks Wealth Advisors’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-6
Closed -$76 – 819
2026
Q1 		$76 Buy
+6
New +$80 ﹤0.01% 2267

Other funds holding ENTA

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KAM
Krensavage Asset Management New York $263M AUM 66.99% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SSC
Spruce Street Capital New York $510M AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Twin Peaks Wealth Advisors's ENTA Position: Q2 2026 in Review

Twin Peaks Wealth Advisors sold out of Enanta Pharmaceuticals (ENTA) in Q2 2026, closing a stake of 6 shares — an estimated $76 sold.

Twin Peaks Wealth Advisors first reported a position in ENTA in Q1 2026 and held it in 1 quarter. The position peaked at $76 in Q1 2026. 123 funds tracked by Wall St. Rank hold ENTA as of Q2 2026.

  • Twin Peaks Wealth Advisors reported no remaining Enanta Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Twin Peaks Wealth Advisors sold 6 Enanta Pharmaceuticals shares in Q2 2026, an estimated $76.
  • Twin Peaks Wealth Advisors first reported a position in Enanta Pharmaceuticals in Q1 2026 and held it in 1 quarter.
  • Twin Peaks Wealth Advisors's Enanta Pharmaceuticals position peaked at $76 in Q1 2026.
  • 123 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2026.

Based on Twin Peaks Wealth Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.